Psyence Biomedical (PBM) Beginning Cash Balance (2022 - 2026)

Psyence Biomedical has reported Beginning Cash Balance for 3 years, with the latest figure at $6.1 million in Q1 2026.

• On a quarterly basis, Beginning Cash Balance changed N/A year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a N/A change from a year earlier, with the FY2026 full-year figure at $6.1 million, changed N/A from the prior year.
• Beginning Cash Balance was $6.1 million for Q1 2026 at Psyence Biomedical, up from $128678.0 in the prior quarter.
• The five-year high for Beginning Cash Balance was $6.1 million in Q1 2026, with the low at $128678.0 in Q3 2023.
• Average Beginning Cash Balance over 3 years is $2.2 million, with a median of $1.2 million recorded in 2022.
• The largest YoY upside for Beginning Cash Balance was 80.15% in 2023 against a maximum downside of 80.15% in 2023.
• Over 3 years, Beginning Cash Balance stood at $648282.0 in 2022, then slumped by 80.15% to $128678.0 in 2023, then jumped by 4667.84% to $6.1 million in 2026.
• The last three Beginning Cash Balance figures came in at $6.1 million (Q1 2026), $128678.0 (Q3 2023), and $1.8 million (Q1 2023), per Business Quant data.